Pershing Edward, CEO, reported a transaction classified as exercise at PROVECTUS BIOPHARMACEUTICALS, INC.. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
CEO
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of…
The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2022 Note") at any time while the 2022 Note…
interest of the 2022 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2022 Not…
On January 30, 2024, the 2022 Note was converted into 51,290 shares of Series D-1 Preferred Stock.
0 other filings
0 recent txs